Lead Sponsor

Lexicon Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients ≥ 18 years of age
•All patients of reproductive potential must agree to use an adequate method of contraception during the study and for 12 weeks after the Follow-up visit.
•Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor
•Documented history of carcinoid syndrome
•Patient is able and willing to provide written informed consent prior to participation

•Presence of diarrhea attributed to any condition other than carcinoid syndrome.
•Presence of 12 or more watery bowel movements per day
•Positive stool examination for enteric pathogens, pathogenic ova or parasites, of Clostridium difficile at Screening
•Karnofsky Performance Status ≤ 60%
•Presence of any clinically significant laboratory, medical history, or physical examination findings deemed unacceptable by the Investigator
•A history of short bowel syndrome
•History of constipation within 2 years of Screening
•Life expectancy \< 12 months from Screening

Related studies

NCT07087054 · Carcinoid Syndrome, Carcinoid, and more

NCT05064514 · Tricuspid Regurgitation, Tricuspid Valve Disease, and more

NCT04993261 · Carcinoid Syndrome, Carcinoid Tumor, and more

NCT03453489 · Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm

NCT04713202 · Neuroendocrine Tumors, Carcinoid Syndrome, and more

Telotristat Etiprate for Carcinoid Syndrome Therapy